Global Autologous Cell Therapy Market Size 2024, Forecast To 2033
6 Mar, 2024
The autologous cell therapy market size has grown rapidly in recent years. It will grow from $8.58 billion in 2023 to $10.22 billion in 2024 at a compound annual growth rate (CAGR) of 19.2%. The growth in the historic period can be attributed to advancements in regenerative medicine, increased prevalence of chronic diseases, enhanced understanding of cellular biology, patient preference for personalized medicine, clinical success and positive outcomes. The autologous cell therapy market size is expected to see rapid growth in the next few years. It will grow to $19.53 billion in 2028 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to continued growth in regenerative medicine, expanding applications across medical specialties, advancements in cell culture techniques, increasing investment and research initiatives, regulatory support and standardization. Major trends in the forecast period include development of automated manufacturing technologies, integration of biomarkers in treatment strategies, emergence of point-of-care cell processing, expansion beyond hematopoietic stem cells, collaborations and partnerships in the industry.
Global Autologous Cell Therapy Market Key Driver
The autologous cell therapy market is poised for growth, propelled by the high prevalence of chronic diseases. Chronic diseases, characterized by conditions requiring ongoing medical treatment lasting more than a year, represent a significant healthcare challenge. Autologous cell therapy emerges as a promising approach for managing such conditions, utilizing an individual's cells cultivated and expanded outside the body before reintroduction. As of January 2023, the National Library of Medicine projected a notable increase in the number of individuals aged 50 and older in the US with at least one chronic condition, reaching 142.66 million by 2050. This prevalence of chronic diseases underscores the demand for innovative therapeutic approaches like autologous cell therapy, driving the growth of the market. Market size projections for 2023, 2024, and 2028 reflect this anticipated growth trajectory.
Get A Free Sample Of The Global Autologous Cell Therapy Market ReportGlobal Autologous Cell Therapy Market Segments
The autologous cell therapy market covered in this report is segmented –
1) By Therapy: Autologous Stem Cell Therapy, Autologous Cellular Immunotherapies
2) By Source: Bone Marrow, Epidermis, Mesenchymal Stem Cells, Hematopoietic Stem Cells, Chondrocytes, Other Sources
3) By Application: Cancer, Neurodegenerative Disorders, Cardiovascular Disorders, Autoimmune Disorders, Orthopedics, Wound Healing, Other Applications
4) By End User: Hospitals And Clinics, Ambulatory Centers, Academics And Research, Other End-Users
By Geography:The regions covered in the autologous cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the autologous cell therapy market in 2023. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Autologous Cell Therapy Industry Players
Bristol-Myers Squibb Company, Novartis AG, Vericel Corporation, Holostem Terapie Avanzate S.r.l., Pharmicell Co. Ltd., Opexa Therapeutics Inc., Tego Science AB, Brainstorm Cell Therapeutics Inc., Caladrius Biosciences Inc., Lineage Cell Therapeutics Inc., Castle Creek Biosciences Inc., Gilead Sciences Inc., Johnson & Johnson, CORESTEM Inc., Dendreon Pharmaceuticals LLC, Medipost Co. Ltd., PharmaJet Inc., Bioject Medical Technologies Inc., Medical International Technology Inc., INJEX Pharma AG, Lonza Group Ltd., Corning Incorporated, Takeda Pharmaceutical Company Limited, CSL Limited, AstraZeneca plc, Moderna Inc., Sinovac Biotech Ltd., Valneva SE, Bavarian Nordic A/S, Dynavax Technologies Corporation
Get The Full Global Autologous Cell Therapy Market ReportAutologous Cell Therapy Market Overview
Autologous cell therapy refers to a type of cell therapy where a patient's own cells are collected, processed, and then reintroduced into their own body for therapeutic purposes. It is often used in regenerative medicine to repair, replace, or restore damaged tissues or organs.
Autologous Cell Therapy Global Market Report 2023 provides data on the global autologous cell therapy market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The autologous cell therapy market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.